Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Puts U.S. Consumer Business On The Selling Block

This article was originally published in The Pink Sheet Daily

Executive Summary

The company plans to contact potential buyers for the OTC business "over the coming weeks." Novartis and GSK are understood to be interested in Bristol's North American consumer business.

You may also be interested in...



Teva Loses Pravachol Exclusivity Period; Multiple Generics To Launch In 2006

FDA tells Teva that the 180-day exclusivity period for three pravastatin doses expired in February. As a result, as many as six companies – including Teva – could be in a position to launch generic Pravachol when Bristol’s composition of matter patent expires in April 2006. Teva plans to sue FDA to reinstate its first-to-file exclusivity period.

Teva Loses Pravachol Exclusivity Period; Multiple Generics To Launch In 2006

FDA tells Teva that the 180-day exclusivity period for three pravastatin doses expired in February. As a result, as many as six companies – including Teva – could be in a position to launch generic Pravachol when Bristol’s composition of matter patent expires in April 2006. Teva plans to sue FDA to reinstate its first-to-file exclusivity period.

Pravachol OTC Deal Reached Between Bayer, Bristol

Bristol will handle the regulatory filing of the switch NDA and advisory committee presentation for pravastatin 20 mg, while Bayer Consumer Care will handle OTC sales and marketing if FDA approves the cholesterol-lowering agent for nonprescription sale.

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel